Nicolas Marincek

Indium-111 labeled gold nanoparticles for in-vivo molecular targeting.

Thomas Krause, Lorenz Meier, Martin A Walter, 2014, Biomaterials.

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.

Matthias Briel, Helmut Rasch, Christian Schindler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.

C. Rochlitz, M. Briel, M. Walter, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

L. Bubendorf, M. Briel, M. Walter, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

C. Rochlitz, M. Briel, M. Walter, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Somatostatin Receptor–Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

M. Briel, M. Walter, J. Müller-Brand, 2015, The Journal of Nuclear Medicine.

Upregulation of Key Molecules for Targeted Imaging and Therapy

M. Walter, C. Stettler, P. Radojewski, 2016, The Journal of Nuclear Medicine.

Towards tailored radiopeptide therapy

M. Briel, M. Walter, P. Radojewski, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma.

C. Rochlitz, M. Briel, M. Walter, 2015, American journal of nuclear medicine and molecular imaging.

BRIEF COMMUNICATION Somatostatin receptor targeted radiopeptide therapy with yttrium-90-DOTATOC and lutetium-177-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial

M. Briel, M. Walter, P. Radojewski, 2015 .

Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors

M. Walter, J. Beyersmann, M. Laimer, 2017, The Journal of Nuclear Medicine.